iShares US Pharmaceuticals ETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.
iShares U.S. Pharmaceuticals ETF IHE
Morningstar’s Analysis IHE
Will IHE outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 79.0
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Eli Lilly and Co | 23.71 | 381M | Healthcare |
Johnson & Johnson | 22.45 | 361M | Healthcare |
Pfizer Inc | 4.69 | 75M | Healthcare |
Viatris Inc | 4.55 | 73M | Healthcare |
Merck & Co Inc | 4.52 | 73M | Healthcare |
Royalty Pharma PLC Class A | 4.41 | 71M | Healthcare |
Bristol-Myers Squibb Co | 4.38 | 70M | Healthcare |
Zoetis Inc Class A | 4.37 | 70M | Healthcare |
Jazz Pharmaceuticals PLC | 3.43 | 55M | Healthcare |
Elanco Animal Health Inc | 2.47 | 40M | Healthcare |